A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)

Yutaka Ogata,Mototsugu Shimokawa,Takaho Tanaka,Yasunori Emi,Eiji Oki,Hiroshi Saeki,Noriaki Sadanaga,Tetsuya Kusumoto,Tetsuo Touyama,Masami Kimura,Hideo Baba,Yoshito Akagi,Kazuo Shirouzu,Yoshihiko Maehara

A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902)

2016

Yutaka Ogata
Mototsugu Shimokawa
Takaho Tanaka
Yasunori Emi
Eiji Oki
Hiroshi Saeki
Noriaki Sadanaga
Tetsuya Kusumoto
Tetsuo Touyama
Masami Kimura
Hideo Baba
Yoshito Akagi
Kazuo Shirouzu
Yoshihiko Maehara

Background This study was designed to evaluate the efficacy and safety of XELOX plus bevacizumab in a Japanese metastatic colorectal cancer population that included elderly patients.

Keywords:

Neutropenia
Prospective cohort study
Bevacizumab
Capecitabine
Fluorouracil
Colorectal cancer
Population
Oncology
Deoxycytidine
Internal medicine
Medicine
Surgical oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations